We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cardiovascular Systems (CSII) Coronary OAS Study Data Favorable
Read MoreHide Full Article
Cardiovascular Systems, Inc. recently released results from a real-world optical coherence tomography (OCT) imaging study at EuroPCR 2021 of Coronary Orbital Atherectomy System (OAS) patients. Notably, the study showed exceptional performance with Diamondback 360 coronary OAS dual mode of action.
For investors’ note, Diamondback 360 Coronary OAS unique mechanism of action utilizes a patented combination of centrifugal force and differential sanding to safely and simply lessen arterial calcium, enabling successful stent delivery.
With the latest achievement, Cardiovascular Systems is likely to strengthen its coronary artery disease (CAD) products business.
More on the Study
The study included 25 patients with severely calcified lesions identified by coronary angiography, registered and treated by a single operator. Every patient got a pre-specified treatment algorithm, including minimum three runs of orbital atherectomy at low speed with OCT imaging pre- and post-OAS prior to stenting.
This strategy of peri-procedural OCT imaging in combination with lower speed orbital atherectomy is a paradigm shift in the effective treatment of the calcified coronary tree, and represents a new standard for patient outcomes and safety.
Study Findings
Severe calcification in coronary lesions slows down optimal stent delivery, expansion and apposition leading to high procedural complications and overall inferior results. The Diamondback 360 Coronary OAS employs a powerful dual mechanism of action to treat both superficial and deep calcium, thus helps in restoring native vessel compliance, simplifying procedural workflow, and enhancing percutaneous coronary intervention outcomes.
The study also demonstrates the benefits of imaging to optimize vessel preparation and reinforces the efficacy of orbital atherectomy’s unique mechanism of action, which both ablate and fracture calcium.
Notable Developments
In March 2021, Cardiovascular Systems announced the acquisition of a line of peripheral support catheters from WavePoint Medical, LLC. The addition of these products to Cardiovascular Systems’ portfolio extends the company’s ability to facilitate physicians to enhance the outcomes for patients undergoing complex peripheral and coronary interventions procedure. Additionally, the successful progress of a portfolio of CTO products will expand Cardiovascular Systems’ existing offering of coronary support products.
In February 2021, Cardiovascular Systems announced the first commercial use of the Diamondback 360 Coronary OAS in Europe. The first patient in Europe has been successfully treated with Diamondback 360 Coronary OAS.
Industry Prospects
Per a report by MarketsandMarkets, the global atherectomy devices market was valued at $1.08 billion and is projected to reach a worth of $1.45 billion by 2022, at a CAGR of 6.1%. The market is primarily growing on an expanding target patient population, continuous product development and commercialization, favorable medical reimbursements, and rising demand for minimally-invasive atherectomy procedures.
Price Performance
Over the past six months, shares of the company have gained 10.2% compared with the industry’s growth of 5.5%.
Zacks Rank and Key Picks
Currently, the company carries a Zacks rank #4 (Sell).
National Vision has a projected long-term earnings growth rate of 23%.
Boston Scientific has a projected long-term earnings growth rate of 9%.
Envista Holdings has an estimated long-term earnings growth rate of 26%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Image: Bigstock
Cardiovascular Systems (CSII) Coronary OAS Study Data Favorable
Cardiovascular Systems, Inc. recently released results from a real-world optical coherence tomography (OCT) imaging study at EuroPCR 2021 of Coronary Orbital Atherectomy System (OAS) patients. Notably, the study showed exceptional performance with Diamondback 360 coronary OAS dual mode of action.
For investors’ note, Diamondback 360 Coronary OAS unique mechanism of action utilizes a patented combination of centrifugal force and differential sanding to safely and simply lessen arterial calcium, enabling successful stent delivery.
With the latest achievement, Cardiovascular Systems is likely to strengthen its coronary artery disease (CAD) products business.
More on the Study
The study included 25 patients with severely calcified lesions identified by coronary angiography, registered and treated by a single operator. Every patient got a pre-specified treatment algorithm, including minimum three runs of orbital atherectomy at low speed with OCT imaging pre- and post-OAS prior to stenting.
This strategy of peri-procedural OCT imaging in combination with lower speed orbital atherectomy is a paradigm shift in the effective treatment of the calcified coronary tree, and represents a new standard for patient outcomes and safety.
Study Findings
Severe calcification in coronary lesions slows down optimal stent delivery, expansion and apposition leading to high procedural complications and overall inferior results. The Diamondback 360 Coronary OAS employs a powerful dual mechanism of action to treat both superficial and deep calcium, thus helps in restoring native vessel compliance, simplifying procedural workflow, and enhancing percutaneous coronary intervention outcomes.
The study also demonstrates the benefits of imaging to optimize vessel preparation and reinforces the efficacy of orbital atherectomy’s unique mechanism of action, which both ablate and fracture calcium.
Notable Developments
In March 2021, Cardiovascular Systems announced the acquisition of a line of peripheral support catheters from WavePoint Medical, LLC. The addition of these products to Cardiovascular Systems’ portfolio extends the company’s ability to facilitate physicians to enhance the outcomes for patients undergoing complex peripheral and coronary interventions procedure. Additionally, the successful progress of a portfolio of CTO products will expand Cardiovascular Systems’ existing offering of coronary support products.
In February 2021, Cardiovascular Systems announced the first commercial use of the Diamondback 360 Coronary OAS in Europe. The first patient in Europe has been successfully treated with Diamondback 360 Coronary OAS.
Industry Prospects
Per a report by MarketsandMarkets, the global atherectomy devices market was valued at $1.08 billion and is projected to reach a worth of $1.45 billion by 2022, at a CAGR of 6.1%. The market is primarily growing on an expanding target patient population, continuous product development and commercialization, favorable medical reimbursements, and rising demand for minimally-invasive atherectomy procedures.
Price Performance
Over the past six months, shares of the company have gained 10.2% compared with the industry’s growth of 5.5%.
Zacks Rank and Key Picks
Currently, the company carries a Zacks rank #4 (Sell).
A few better-ranked stocks from the broader medical space are National Vision Holdings, Inc. (EYE - Free Report) , Boston Scientific Corporation (BSX - Free Report) and Envista Holdings Corporation (NVST - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1 Rank (Strong Buy) stocks here.
National Vision has a projected long-term earnings growth rate of 23%.
Boston Scientific has a projected long-term earnings growth rate of 9%.
Envista Holdings has an estimated long-term earnings growth rate of 26%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Click here for the 4 trades >>